Showing results (141-150 of 4,234) with videos related to
Sort By:
Pageof 424
Journal for Immunotherapy of Cancer|November 19, 2015
Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patientsJing Li, Raghvendra M Srivastava, Abhinav Ettyreddy, et al.Journal for Immunotherapy of Cancer|November 19, 2015
Erratum to: Immune monitoring technology primerKevin K DobbinJournal for Immunotherapy of Cancer|October 29, 2014
Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodesKarsten A Pilones, Joseph Aryankalayil, James S Babb, et al.Journal for Immunotherapy of Cancer|September 18, 2015
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanomaAhmad A Tarhini, Haris Zahoor, Yan Lin, et al.Journal for Immunotherapy of Cancer|April 21, 2016
Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoidKristen M Beck, Joanna Dong, Larisa J Geskin, et al.Journal for Immunotherapy of Cancer|March 17, 2016
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy studyViktor H Koelzer, Sacha I Rothschild, Deborah Zihler, et al.Journal for Immunotherapy of Cancer|October 27, 2015
Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patientsJithendra Kini Bailur, Evelyna Derhovanessian, Brigitte Gueckel, et al.Journal for Immunotherapy of Cancer|May 5, 2019
Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatmentHamzah Abu-Sbeih, Cynthia Nguyen Tran, Phillip S Ge, et al.Journal for Immunotherapy of Cancer|May 5, 2019
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapyYixin Zhou, Zuan Lin, Xuanye Zhang, et al.Journal for Immunotherapy of Cancer|May 26, 2019
Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapyHyun Gul Yang, Moon Cheol Kang, Tae Yoon Kim, et al.Pageof 424